Coya Therapeutics plans to scale up manufacturing and prepare for the commercialization of COYA 302, its ALS therapy drug. Photo via Getty Images

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

Energy Transfer, a Dallas-based midstream energy company, just donated $100,000 to Houston Methodist. Photo via TMC.edu

Energy co. makes $100,000 donation to Houston hospital

curing ALS

Where do energy transition and life-saving medicine meet? In Texas, of course.

Energy Transfer, a Dallas-based midstream energy company, just donated $100,000 to Houston Methodist. The grant is part of a $200,000 gift that has spanned the past two years. The goal? To eradicate the neurological disorder, ALS (amyotrophic lateral sclerosis). There is currently no cure for ALS. For roughly 90 percent of patients, there’s no known genetic cause, meaning the disease can strike anyone.

Houston Methodist currently has numerous clinical trials taking place with the goal to slow or halt the progression of the degenerative ailment.

“Every dollar donated to ALS research is a beacon of hope for those battling the disease,” said Chris Curia, executive vice president and chief human resources officer at Energy Transfer. “Those affected by ALS deserve a chance at a better life. We are hopeful this donation brings us one step closer to a world without this disease.”

Houston Methodist is home to the first multidisciplinary care clinic for ALS patients in the region and is actively engaged in both clinical and basic scientific research to support people battling ALS.

“We appreciate Energy Transfer’s generosity in our efforts to improve the quality of life and to provide hope for ALS patients and their families. Their continued commitment to Houston Methodist’s ongoing ALS research is truly transformational,” says Stanley H. Appel, M.D., a pioneering neurologist at Houston Methodist whose lab focuses on neurodegenerative diseases, including ALS.

Energy Transfer’s gift will help to support one particularly promising trial of a combination therapy that is currently moving into Phase 2. In its first phase, the therapy was found to safely slow disease progression in four ALS patients over a six-month period. Those patients had no significant progression of their disease during the trial. Prior to receiving the therapy, each of the patients had reported declining abilities to perform daily tasks.

Energy Transfer’s good deed could mean the world not only to patients at Houston Methodist, but to ending ALS altogether.

------

This article originally ran on EnergyCapital.

Daniel Barvin has a neurodegenerative disease in his near future. He joined Houston-based Coya Therapeutics to help fight for a cure to the aggressively deadly ALS. Photo via Getty Images

How this Houston innovator is using his personal connection to ALS fuel his fight for a cure

guest column

We can never predict how our lives will turn out, but then maybe some of us can. Genetic testing showed that I, like my grandfather, aunt, uncle and father before me, would most likely die of amyotrophic lateral sclerosis, more commonly known as ALS, and/or frontotemporal degeneration (FTD) in my 40s.

Being 36, it’s possible that fear could have overtaken my life, but instead I chose to fight for every chance to change not only my life, but the lives of millions who are suffering or may one day suffer from neurodegenerative disease.

ALS is a rare disease that robs one of their ability to control their muscles, leading them to lose their ability to walk, talk and eventually breathe. Eighty percent of cases are sporadic (of unknown origin) and 20 percent have known genetic causes.

When I learned that I carried the C9ORF72 genetic variant, a causative genetic variant for ALS/FTD) my first instincts were to help others understand their status and where they could turn for help. I saw a vacuum for resources and understanding in the genetic ALS space and I knew that thousands were suffering in darkness.

Through the efforts of many, we created the first ever nonprofit – Genetic ALS & FTD: End the Legacy – focused on fighting for the genetic ALS and FTD communities. After making great strides to fight for our rights and access to care, I was asked if I could help my current CEO, Howard Berman, commercialize Dr. Stanley Appel’s regulatory T Cell (Treg) therapy for ALS.

I joined Coya Therapeutics in 2021 as the first employee, working to build a company that would one day bring life changing therapies to patients. Coya’s therapies are based on Dr. Appel’s discovery that neurodegenerative diseases drive an inflammatory response. As inflammation rises, it damages regulatory T cells, and when Tregs are damaged, inflammation becomes a persistent condition driving degeneration and eventually death.

It was at that point that my life changed from the advocacy world to the therapeutic world. Now over three years later, we are closer than ever to making a paradigm change for how patients with ALS and other neurodegenerative diseases are treated.

At Coya, we believe that combination biologics are the future of treating neurodegenerative diseases. COYA 302 is our lead asset, which has shown promising results in a proof-of-concept study released in March of 2023. We are currently working towards a double-blind, placebo-controlled trial for COYA 302 in ALS set to kick off later this year.

I never wanted to live a life so damned by disease, but when put between a rock and a hard place, the only choice is to fight. I don’t know how my life will end, but I hope that my children will know that I faced a great challenge head on with pride and resilience.

In the end, it is the combination of both the worlds I work in that lead to better outcomes for patients, raising awareness and lifesaving research. This ALS Awareness Month, please join us and our partners like the ALS Association, End the Legacy, and I AM ALS in raising awareness about these conditions, their risks, and treatment options.

------

Daniel Barvin is the vice president of operations and patient advocacy at Coya Therapeutics.

For Howard Berman, CEO and co-founder of Coya Therapeutics, commercializing his company is personal. Photo courtesy of Coya

Why this Houston innovator is racing to commercialize its unique treatment for neurodegenerative diseases

HOUSTON INNOVATORS PODCAST EPISODE 182

When Howard Berman sought out renowned Houston Methodist researcher and neurologist Dr. Stanley Appel, he was looking for treatment for his father, who was suffering from dementia. He wasn't looking for a job, but Dr. Appel had other ideas and asked Berman to meet with him.

"I was interested in what I could do for my dad," Berman says on the Houston Innovators Podcast, explaining how he took the meeting with Dr. Appel, who then presented him with some of his research. "By slide five my jaw had hit the ground.

"He had shown that he could stop the progression in one of his early trials of ALS," Berman says.

Not too long after that meeting, Berman, who founded digital health platform imaware, joined Dr. Appel to lead commercialization of Coya Therapeutics, a biotech startup that raised over $20 million in venture funding before going public a few months ago.

Coya has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again. Diseases like ALS, the company's focus right now, prevent T-regs from doing their job in controlling inflammation, and without these cells hard at work, the human body doesn't stand a chance in fighting autoimmune threats.

Berman, as co-founder and CEO, has been at the helm of the company leading it through both the fundraising and IPO processes. Coya's IPO occured in a tough market — only 12 biotech companies went public last year, he explains. To Berman, that just proves how passionate the team was about getting this product to those who need it.

"It really says something for the fortitude and our team to come together to make it happen," he says on the show. "We're able to deliver and execute in a difficult market climate.

"Once you're a public company, you have different expectations," he continues. "But you also have the opportunity to go out and attract additional investors in ways you can't do as a private company."

For Berman, whose father passed away earlier this year, it's a personal motivation that drives him to lead the company — as well as an opportunity to advance the city of Houston.

"The next number of years as we develop this therapeutic regimen for ALS, we have the potential to transform Houston into something more than it is currently," he says. "Our success will be the city's success."

Berman shares more of the Coya Therapeutics story on the podcast, as well as how he sees Houston's potential as an emerging hub for biotech. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

University of Houston med school secures full accreditation

med school milestone

The University of Houston’s Tilman J. Fertitta Family College of Medicine has officially earned full accreditation after launching six years ago.

The designation comes from the Liaison Committee on Medical Education, which granted UH the maximum five-year review period available to a new medical school. To achieve the status, the committee reviewed the Fertitta College of Medicine's facilities, faculty and student outcomes, and curriculum to ensure the college met the highest standards in medical education.

“Full accreditation is not the finish line — it’s the foundation for everything we hope to accomplish in the years ahead,” Dr. Jonathan McCullers, vice president for health affairs at UH and dean of the Fertitta College of Medicine, said in a news release. “It strengthens our ability to attract outstanding students and faculty, expand our partnerships and prepare the next generation of physicians.”

Fertitta College of Medicine has graduated three classes of physicians, and every graduate from its most recent class secured a residency position. Enrollment has expanded from 30 students in its inaugural class to 65 students in its current class.

According to UH, about 70 percent of graduates have chosen to remain in Texas for further training, which is key to addressing the estimated 10,000 doctors needed to meet growing needs.

Fertitta College of Medicine opened for its first students in 2020, and now joins 14 other Texas schools as a fully LCME-accredited medical school. It also joins UTHealth Houston's McGovern Medical School and Baylor College of Medicine as one of three Houston-based LCME-accredited campuses.

The news comes after UH launched its health enterprise initiative, UH Health, in July and broke ground on its $77.5 million Medical Research Building next to the Fertitta College of Medicine last month.

“Building a medical school from the ground up is an extraordinary undertaking, and this milestone reflects the dedication of everyone who helped make it happen,” Dr. Stephen Scott, vice dean for education at the Fertitta College of Medicine, added in the release. “From developing an innovative curriculum to establishing the systems and partnerships that support our students, this has been a true team effort.”

Woodlands startup Mavria raises $130M to mass-produce AI data centers

seed funding

The Woodlands-based Mavria, which mass-produces factory-built modular AI data centers, just emerged from stealth mode with $130 million in funding at a $1 billion valuation.

Mavria raised the money in pre-seed and seed rounds led by Paradigm, an investment firm that concentrates on early-stage startups developing “pioneer” technology. Participants in the funding rounds include AMP PBC, Critical Frontier, Dream Ventures and Liquid 2 Ventures, co-founded by former NFL quarterback Joe Montana.

The company’s inaugural product, Terrain, is a prefabricated data center designed for AI labs, cloud computing providers and data center developers. Mavria says its platform avoids ground-up construction, delivering infrastructure more quickly and at a lower cost.

Mavria tells the Wall Street Journal that the first Terrain unit is being built at a Houston-area factory. The 5-megawatt Terrain system features power distribution, direct liquid cooling, controls and server racks.

“America sets the pace at the intelligence frontier. But the race is moving from the lab into the physical world,” Adam Blake, co-founder and CEO of Mavria, wrote in a blog post.

“Intelligence needs data centers. Data centers need power. Power needs factories, equipment, supply chains, and skilled workers, but much of that infrastructure is still built one custom project at a time, on timelines measured in years.”

Blake and Mavria’s two other co-founders, Nick Poradek and Seth Cohen, most recently worked at the U.S. Department of Energy. There, they focused on reforming the nuclear power sector.

From start to finish, it can take roughly three to six years to build a data center at an estimated cost of $10 million to $37 million per megawatt. Based on those figures, a 100-megawatt data center might cost as much as $3.7 billion.

Here are brief bios of Blake, Poradek and Cohen, who co-founded Mavria in May.

Adam Blake

Blake most recently was a senior advisor to U.S. Energy Secretary Chris Wright. He is co-founder and former CEO of Zego, a provider of energy management technology for property managers. Zego spun out from Brightergy, a commercial solar company. Blake is founder and former CEO of Brightergy.

Nick Poradek

Poradek, chief operating officer at Mavria, was also an advisor to the U.S. energy secretary. He is founder and former CEO of Spring-based Edera Energy, co-founder of The Woodlands-based craft-ice brand Clarity Ice, and founder and former CEO of The Woodlands-based Edera Capital. Poradek sold Edera Energy, a manufacturer of oilfield equipment, to Liberty Energy, a fracking company. Wright is Liberty’s founder and former chairman and CEO.

Seth Cohen

Cohen, chief strategy officer and chief legal officer at Mavria, was head of nuclear law and policy at the Department of Energy. He is also a former NASA advisor and a former attorney at Kirkland & Ellis.

“We believe in rapidly deploying infrastructure as a product, rather than custom-building every project,” Blake said. “We’re bringing together engineering, manufacturing, supply chains and capital so that every project makes us better at delivering the next.”